ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Voelkel, N.
Right arrow Articles by Tuder, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Voelkel, N.
Right arrow Articles by Tuder, R.
Eur Respir J 1999; 14: 1246-1250
Copyright © ERS Journals Ltd 1999

Original Articles

Severe pulmonary hypertensive diseases: a perspective

NF Voelkel and RM Tuder

Clinically "severe pulmonary hypertension" is a group of diseases. The nomenclature of pulmonary hypertensive disorders is confusing since terms like "primary", "idiopathic", "unexplained" and "plexogenic" are often used interchangeably. In this Point of view or perspective the authors challenge the validity of the traditional pathohistological classification as it had been provided by HEATH and EDWARDS [1]. A classification that is focused on histological and clinical association is proposed and a recommendation to reorder "Severe pulmonary hypertension" in an association-morphology-function context is provided. The purpose of this "perspective" is to stimulate a discussion which hopefully will lead to a change in the presently used nomenclature and classification of pulmonary hypertensive disorders.


This article has been cited by other articles:


Home page
 Physiol. GenomicsHome page
L. Moreno-Vinasco, M. Gomberg-Maitland, M. L. Maitland, A. A. Desai, P. A. Singleton, S. Sammani, L. Sam, Y. Liu, A. N. Husain, R. M. Lang, et al.
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension
Physiol Genomics, April 1, 2008; 33(2): 278 - 291.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. Asosingh, M. A. Aldred, A. Vasanji, J. Drazba, J. Sharp, C. Farver, S. A.A. Comhair, W. Xu, L. Licina, L. Huang, et al.
Circulating Angiogenic Precursors in Idiopathic Pulmonary Arterial Hypertension
Am. J. Pathol., March 1, 2008; 172(3): 615 - 627.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. W. Geraci, M. Moore, T. Gesell, M. E. Yeager, L. Alger, H. Golpon, B. Gao, J. E. Loyd, R. M. Tuder, and N. F. Voelkel
Gene Expression Patterns in the Lungs of Patients With Primary Pulmonary Hypertension : A Gene Microarray Analysis
Circ. Res., March 30, 2001; 88(6): 555 - 562.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
L. TARASEVICIENE-STEWART, Y. KASAHARA, L. ALGER, P. HIRTH, G. MC MAHON, J. WALTENBERGER, N. F. VOELKEL, and R. M. TUDER
Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension
FASEB J, February 1, 2001; 15(2): 427 - 438.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. NISHIMURA, J. L. FAUL, G. J. BERRY, I. VEVE, R. G. PEARL, and P. N. KAO
40-O-(2-Hydroxyethyl)-rapamycin Attenuates Pulmonary Arterial Hypertension and Neointimal Formation in Rats
Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 498 - 502.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. L. FAUL, T. NISHIMURA, G. J. BERRY, G. V. BENSON, R. G. PEARL, and P. N. KAO
Triptolide Attenuates Pulmonary Arterial Hypertension and Neointimal Formation in Rats
Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2252 - 2258.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the European Respiratory Society.